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ABSTRACT
Objectives: Sickle With Ibuprofen and Morphine
(SWIM) trial was designed to assess whether
co-administration of ibuprofen (a non-steroidal
anti-inflammatory drug) resulted in a reduction of
opioid consumption delivered by patient-controlled
analgesia (PCA) for acute pain in sickle cell disease.
Design: A randomised, placebo-controlled, double-
blind trial.
Setting: UK multicentre trial in acute hospital setting.
Participants: Adults with sickle cell disease of any
gender and phenotype aged 16 years and over.
Interventions: Oral ibuprofen at a dose of 800 mg
three times daily or placebo in addition to opioids
(morphine or diamorphine) administered via PCA
pump for up to 4 days.
Main outcome measures: The primary outcome
measure was opioid consumption over 4 days
following randomisation.
Results: The SWIM trial closed early because it failed
to randomise to its target of 316 patients within a
reasonable time.
Conclusions: The key issues identified include the
unanticipated length of time between informed consent
and randomisation, difficulties in randomisation of
patients in busy emergency departments, availability of
trained staff at weekends and out of hours, fewer
centres than expected using PCA routinely for sickle
cell pain treatment, lack of research staff and support
for participation, and the trial design. There are
implications for future UK trials in sickle cell disease.
Trial registration number: ISRCTN97241637,
NCT00880373; Pre-results.
BACKGROUND
Sickle cell disease comprises a group of
genetic blood disorders that affect over 13 000
people in the UK predominantly of African,
Caribbean, Asian, Arabian and Mediterranean
origin. The hallmark symptom is pain. Over
50% of patients with sickle cell disease admit-
ted to hospital in the UK have acute pain,1
commonly treated with opioids2 with
unpleasant side effects including nausea, con-
stipation, itching, sedation and emotional
changes.
Non-steroidal anti-inﬂammatory drugs
(NSAIDs) have been trialled in sickle cell
disease and are recommended.3 However, a
trial comparing ketoprofen with placebo plus
syringe pump-administered morphine in sickle
cell disease failed to demonstrate a morphine
sparing effect.4 Ibuprofen analgesia is dose-
related: a single 400 mg dose offers one in
three patients with moderate-to-severe pain at
least 50% relief (number-needed-to-treat
(NNT) of 2.7), compared with placebo; a
single 600 mg dose provides at least 50% pain
relief to one in two patients (NNT of 1.7).5
Furthermore, patient-controlled analgesia
(PCA) using morphine in sickle cell disease
provides adequate pain relief with reduced
opioid consumption compared with continu-
ous infusion.6
METHODS
‘Sickle With Ibuprofen and Morphine’
(SWIM) trial, the ﬁrst UK multicentre trial of
analgesia in sickle cell disease, was a rando-
mised, placebo-controlled, double-blind trial
of ibuprofen or placebo, designed to deter-
mine whether ibuprofen could reduce PCA
opioid consumption for acute sickle cell
pain.
Strengths and limitations of this study
▪ The SWIM trial was designed as a randomised,
placebo-controlled, double-blind trial.
▪ SWIM failed to achieve its target rate of patient
randomisation.
▪ The implications for future UK sickle cell trials
are discussed.
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The National Research Ethics Service, and Medicines
and Healthcare products Regulatory Agency approved the
SWIM trial.
Participants and recruitment
Participants were adults (aged 16 years and over) with
sickle cell disease of any phenotype, admitted to hospital
with acute sickle cell pain for which opioids were war-
ranted. Exclusions were contraindications to morphine,
diamorphine, or ibuprofen including peptic ulcers and
NSAID-induced asthma; renal dysfunction; stroke in pre-
ceding 6 weeks; pregnancy or breastfeeding.
Recruitment was in two stages:
1. Screening, informed consent and trial registration in
outpatient clinics
2. Verbal assent and randomisation in Emergency
Departments (A&E) on admission for sickle cell pain
requiring opioid analgesia.
Sample size calculation assumed a mean opioid con-
sumption in the control group of 33 mg (SD 43) over
4 days.6 To detect a 50% reduction (90% power, 5% sig-
niﬁcance) required 286 patients; the recruitment target
of 316 (158 per arm) allowed for 10% attrition.
Patients were randomised (1:1) to oral ibuprofen
800 mg three times daily, or matching placebo, in addition
to morphine or diamorphine via PCA for a maximum of
4 days during hospitalisation. Randomisation used per-
muted blocks stratiﬁed by centre; each patient was rando-
mised only once by assigning the patient to the next
available treatment pack number with the allocation
sequence generated by the MRC Clinical Trials Unit.
The primary outcome was opioid consumption over
4 days.
RESULTS
Daily pain and symptom scores were recorded over the
4 days (table 1). Treatment effects and 95% CIs were cal-
culated using an unadjusted linear regression model.
The SWIM trial was terminated early by the NIHR
HTA Programme due to the very slow randomisation
rate. Patients were recruited over 16 months; 83 con-
sented to the trial but only 7 patients were randomised
(ﬁgure 1). Two main issues emerged at closure. First,
although the number of patients giving their consent
increased steadily, there was often a long delay between
consent and randomisation. Patients with sickle cell
disease have unpredictable pain episodes, some of which
may require A&E attendances and hospital admissions.
Severely affected patients tend to be offered disease-
modifying treatment such as hydroxycarbamide (hydro-
xyurea) or blood transfusions. During the trial period,
most patients who had given their consent did not have
a sickle cell pain episode that required hospitalisation.
One patient was admitted to another hospital which was
not a trial centre at the time. Second, there was a low
rate of participation by sickle cell disease treatment
centres; 27 were approached, 5 did not respond, 12
declined, 10 expressed interest, 4 registered patients and
only 2 centres randomised patients (table 2).
DISCUSSION
Several contributory factors for early closure of the
SWIM trial, and potential remedies were identiﬁed:
1. Monitoring of emergency admissions for sickle cell
pain at the lead trial centre found that 11 registered
patients were not randomised because they presented
at A&E during weekends or at night when no SWIM
trial trained staff were present. Good Clinical Practice
(GCP) training of A&E staff performing randomisa-
tion was challenging due to high staff turnover. A
SWIM trial-speciﬁc GCP training package was devel-
oped, which was easier to deliver on a more frequent
basis, but there was insufﬁcient time for this to have
an impact on randomisation rate.
2. A&E at the lead centre was closed overnight for a sig-
niﬁcant proportion of the study due to low stafﬁng
levels and safety concerns. Therefore, some regis-
tered patients were admitted to other centres. A
system to allow randomisation of a registered patient
admitted at a different centre was planned which
would have improved the randomisation rate.
3. A SWIM trial protocol amendment to allow random-
isation for repeated admissions had been approved
Table 1 Clinical outcomes for each treatment arm
Ibuprofen
(n=2)
Placebo
(n=5)
Difference in means
(Ibuprofen vs placebo)
(95% CI)
Opioid consumption over 4 days (mg)—mean (SD) 110 (45) 206 (104) −96 (−301 to 109)
Pain score over 4 days*—mean (SD) 1.5 (0.7) 3.2 (1.4) −1.7 (−4.4 to 1.1)
Number of self-reported side effects per patient† (mild, moderate, or
severe)—mean (SD)
7.5 (0.7) 10.2 (2.2) −2.7 (−6.9 to 1.5)
Number of self-reported side effects per patient† (severe)—mean (SD) 3.0 (1.4) 3.2 (3.1) −0.2 (−6.3 to 5.9)
*Pain scores were measured using a 10-point scale (0–10) with higher scores indicating more pain.
†Self-reported side effects included nausea, vomiting, diarrhoea, constipation, stomach pain/discomfort, blood in stool, mood/emotional
changes, sleep disturbances, dizziness, headache, itching, dry mouth, sore chest, and breathing difficulties, and each symptom was graded
as none, mild, moderate, or severe.
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by the trial oversight committees but not implemen-
ted before closure.7
4. The SWIM trial was adopted onto the National
Institute for Health Research Clinical Research
Network (NIHR CRN) portfolio. Nonetheless, initi-
ation of trial centres was slow and research support
was difﬁcult to access. Several interested centres
could not participate because they did not use opioid
PCA. Other reasons included lack of research infra-
structure and anticipated difﬁculties with randomisa-
tion in busy A&Es.
5. Many recruited patients with sickle cell disease did
not have frequent hospitalisations for pain episodes,
with a longer than anticipated delay between consent
and randomisation, although it was encouraging that
only 25% of eligible patients declined to participate.
The SWIM trial was conducted within the UK
National Health Service (NHS) and was unsuccessful
due to lack of interest or capacity at several large sickle
cell disease centres, overestimation of the number of eli-
gible patients, and unanticipated delays between registra-
tion and randomisation. USA trials in sickle cell disease
also failed to recruit.8–10 Explanations cited include
complex protocol design, insufﬁcient staff, lack of
research support, time constraints of clinical staff,
requirement for trained staff at weekends and out of
hours, involvement of multiple departments and fewer
than expected eligible or consenting patients. These
reasons are similar to the SWIM trial; nonetheless, spe-
ciﬁc strategies have to be adopted in the UK which has a
different health service structure and no strong culture
of sickle cell disease research to encourage successful
participation. Moreover, in a cohort of multicentre trials
funded by either the UK Medical Research Council or
Health Technology Assessment Programme (HTA), only
31% of the trials achieved their original recruitment
target with 53% being awarded an extension, and this
did not improve over time.11 Some preidentiﬁed trial
Figure 1 Flow chart of patient recruitment at SWIM trial closure.
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centres did not participate as planned, and there were
delays due to various reasons including issues with local
research staff and clinical arrangements, logistics and
regulatory approvals although cancer trials were more
successful because of the previously established National
Cancer Research Network.11 Therefore, it appears that
specialty clinical research networks such as those 30
prioritised by the National Institute of Health Research
(NIHR) for clinical research networks subsequent to the
earlier ones in the areas of medicines for children,
stroke, diabetes and Alzheimer’s disease would enhance
recruitment.
There is a clinical need for research to improve treat-
ment and outcomes in sickle cell disease within the NHS.
The NIHR CRN portfolio provides funding; however, this
is based on patients randomised, rather than patients
giving consent and then recruited. In addition, CRN
research capacity funds are usually awarded competitively
based on research activity. Therefore, research inactive
sickle cell disease centres are unlikely to be awarded
funds for staff or capacity building to enable participation
in trials such as SWIM. A case could be made for research
in sickle cell disease to be afﬁliated to a specialty network
to overcome these barriers.
Many HTA-funded trials incorporate a feasibility phase.
The SWIM trial was in response to a priority commissioned
funding opportunity, and no preliminary work had been
done to identify potential problems in recruitment. Six
monthly progress reports highlighted recruitment pro-
blems. Plans to address these included an amendment of
the original trial design to allow each patient to be rando-
mised on more than one occasion, as opposed to partici-
pating only once. This could have increased the accrual
rate during the ﬁrst year by an additional 13 randomisa-
tions. An extension of the trial was proposed to the HTA
Board; however, this would have required additional
funding, hence closure was not avoided.
These issues need to be addressed otherwise sickle
cell disease trials in the UK will continue to fail.
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